(Original title: After the daily limit for two consecutive trading days, Seri Medical reminded the controlling shareholder that the agreement to transfer shares is still in the negotiation stage)
On the evening of January 18, Seri Medical (603716), which has been trading at the daily limit for two consecutive trading days, issued an announcement on abnormal fluctuations in stock trading.
In terms of major matters, the company said that after the company’s self-examination and verification by sending a letter to the controlling shareholder Saihai Technology and the company’s actual controller, Wen Wei, as of the date of the announcement, Saihai Technology had introduced institutional investors and improved its corporate governance structure due to normal business needs. Considering that it is preparing to reduce the company’s shares through agreement transfer (the “Indicative Announcement on the Transfer of Partial Shares and Equity Changes by Controlling Shareholders Agreement” disclosed by the company on November 5, 2021 has given relevant reminders), and it is still In the negotiation stage, there are still great uncertainties in related matters.
“In addition, the company, the company’s controlling shareholder and the company’s actual controller do not have any material information related to the listed company that should be disclosed but not disclosed, including but not limited to major asset restructuring, acquisition, debt restructuring, business restructuring, asset divestiture, Asset injection, share repurchase, equity incentives, bankruptcy reorganization, major business cooperation and other major events that have a greater impact on the company’s stock transaction price.” Saili Medical said.
A reporter from Securities Times・e Company noticed that according to the company’s indicative announcement plan on November 5 last year, Saihai Technology had planned to transfer its 5% shares of Seli Medical’s total share capital to Yanfeng Investment and transfer The price is 13.63 yuan per share, and the total transfer price is 140 million yuan. After the completion of the transfer, the total shareholding ratio of Saihai Technology and its concerted actor Wen Wei decreased from 41.88% to 36.88%.
The announcement on November 5 also reminded that in addition to the controlling shareholder’s previous shareholding reduction plan and this change in equity, there will be a shareholding reduction plan in the next 12 months. It is expected to reduce about 5% of the company’s total shares through agreement transfer The purpose is to introduce strategic investors and optimize the corporate governance structure. If the relevant reduction is implemented, the controlling shareholder and actual controller will not change.
In this change announcement, it is further clarified that “the controlling shareholder is preparing to reduce the company’s shares through agreement transfer, and it is still in the negotiation stage…”
According to the data, Seri Medical is committed to becoming a leading service provider in the operation and management of medical smart supply chain driven by “technology + service”; SPD) as the foundation, and at the same time, it is a development strategy of coordinated deployment to the upstream advanced technology and the out-of-hospital toC-end patient diagnosis and treatment service market (chronic disease management PBM, Internet home medical treatment).
Regarding the latest production and operation situation, the company stated in this change announcement that after the company’s self-examination, the company’s production and operation activities are all normal at present, the market environment and industry policies have not undergone major adjustments, the company’s subordinate businesses are carried out normally, and internal production and operation. The order is normal.
It is worth noting that with the recent outbreak of the epidemic, manufacturers of testing reagents related to the new coronavirus have been sought after by the capital market. In this context, the share price of Seri Medical has also seen a surge, with a cumulative increase of 45.31% since January.
In this transaction announcement, Seri Medical also clarified related businesses: the new coronavirus antigen detection kit independently developed by the company has obtained EU CE certification and can be sold in the EU market, but the above product certification is not exclusive to the company. There are many similar products or other testing products in the market, and the company’s products have not yet been sold in the EU, which has no significant impact on the company’s performance. Investors are advised to pay attention to investment risks, make rational decisions, and invest prudently.
“At the same time, affected by various factors such as the development and control of the overseas epidemic, the choice of testing methods, the strength of overseas market promotion, and the degree of customer recognition, the sales of the above-mentioned new crown products in the future are subject to greater uncertainty.” Saili Medical reminded say.